Clinical trials: Becotatug Vedotin
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, controlled, Phase II clinical study designed to evaluate the efficacy and safety of neoadjuvant and adjuvant therapy with vebikotamab combined with Pucotenlimab compared to standard treatment in…
- Trial name
- BLOOM-ON (NCT07632339)
- Testing
- Becotatug Vedotin combined with Pucotenlimab, surgery
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)
The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of Becotatug Vedotin with Pucotenlimab as a possible neoadjuvant therapyand for locally advanced oral/pharyngeal squamous cell…
- Trial name
- NCT07545083
- Testing
- MRG003+Pucotenlimab
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Penile Cancer
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
Penile cancer is a rare malignant tumor of the male genitourinary system, with 95% being squamous cell carcinoma. Due to social factors, delayed diagnosis is common, leading to a high rate of lymph node metastasis (17%-45% at…
- Trial name
- NCT07497919
- Testing
- Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Cholangiocarcinoma
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations
This study tests whether adding becotatug vedotin (EGFR-ADC) to standard chemotherapy plus immunotherapy improves outcomes compared to chemotherapy plus immunotherapy alone as first-line treatment for patients with advanced or…
- Trial name
- NCT07598318
- Testing
- Becotatug Vedotin, Pucotenlimab, Gemcitabine
- Volunteers
- 164 people
- Sponsor
- Sir Run Run Shaw Hospital
Head and Neck Squamous Cell Carcinoma
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
A multicenter, randomized, double-blind, phase II clinical study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of Becotatug Vedotin for Injection in combination with PD-1 in patients with locally…
- Trial name
- NCT07586124
- Testing
- Becotatug Vedotin for Injection, Pucotenlimab Injection
- Where
- 15 sites in China
- Volunteers
- 80 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-Targeting ADC) in combination with Pucotenlimab and Cisplatin as neoadjuvant therapy for patients with locally advanced head and neck…
- Trial name
- NCT07393477
- Testing
- Combination Therapy with Becotatug Vedotin, Pucotenlimab, and Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
HNPCC
A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma
This study is a randomized, open-label, multi-center phase II trial evaluating the efficacy and safety of the becotatug vedotin in combination with pucotenlimab regimen in patients with advanced head and neck squamous cell…
- Trial name
- NCT07628855
- Testing
- Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Volunteers
- 30 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Relapsed Small Cell Lung Cancer (SCLC)
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer.
- Trial name
- NCT07874581
- Testing
- MRG003 (Becotatug Vedotin)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China